UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

No benefit from the addition of anti-EGFR antibody in all right-sided metastatic colorectal cancer?

Annals of oncology, 2017-08, Vol.28 (8), p.2030-2031

2017

Volltextzugriff (PDF)

An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients

British journal of cancer, 2015-05, Vol.112 (10), p.1709-1716

2015

Volltextzugriff (PDF)

Relation of overall survival, progression free survival, post progression survival and response rate in four randomized Japanese phase III trials comparing various combinations of S-1 therapy for first-line treatment of advanced gastric cancer

Annals of oncology, 2018-10, Vol.29, p.viii231-viii231

2018

Volltextzugriff (PDF)

Phase II study of third-line panitumumab rechallenge in patients with metastatic wild-type KRAS colorectal cancer who achieved a clinical benefit in response to first-line panitumumab plus chemotherapy

Annals of oncology, 2018-06, Vol.29, p.v68-v69

2018

Volltextzugriff (PDF)

Correlation between tumor response to first-line chemotherapy and prognosis in advanced gastric cancer patients

Annals of oncology, 2006-11, Vol.17 (11), p.1665-1672

2006

Volltextzugriff (PDF)

Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05)

Annals of oncology, 2015-09, Vol.26 (9), p.1916-1922

2015

Volltextzugriff (PDF)

RAS mutations in circulating tumor DNA (ctDNA) and clinical outcomes of rechallenge treatments with anti-EGFR antibodies in patients with metastatic colorectal cancer (mCRC)

Annals of oncology, 2019-07, Vol.30, p.iv114-iv114

2019

Volltextzugriff (PDF)

Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer

British journal of cancer, 2003-10, Vol.89 (8), p.1486-1492

2003

Volltextzugriff (PDF)

A biomarker study to validate predictors for clinical outcome of cetuximab based chemotherapy in first-line metastatic colorectal cancer (mCRC) patients: JACCRO CC-05/06AR and FIRE-3

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii162

2018

Volltextzugriff (PDF)

Gene mutation status in circulating tumor DNA (ctDNA) and first-line FOLFOXIRI plus bevacizumab (bev) in metastatic colorectal cancer (mCRC) harboring RAS mutation

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii181-viii182

2018

Volltextzugriff (PDF)

CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy

The pharmacogenomics journal, 2017-12, Vol.17 (6), p.543-550

2017

Volltextzugriff (PDF)

Dynamic changes in RAS gene status in circulating tumour DNA: a phase II trial of first-line FOLFOXIRI plus bevacizumab for RAS-mutant metastatic colorectal cancer (JACCRO CC-11)

ESMO open, 2022-06, Vol.7 (3), p.100512-100512, Article 100512

2022

Volltextzugriff (PDF)

Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16

ESMO open, 2023-10, Vol.8 (5), p.101636-101636, Article 101636

2023

Volltextzugriff (PDF)

Genetic testing for UGT1A128 and 6 in Japanese patients who receive irinotecan chemotherapy

Annals of oncology, 2008-12, Vol.19 (12), p.2089-2090

2008

Volltextzugriff (PDF)

A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials

The pharmacogenomics journal, 2018-01, Vol.18 (1), p.43-48

2018

Volltextzugriff (PDF)

Phase I II study of S-1 combined with irinotecan for metastatic advanced gastric cancer

British journal of cancer, 2006-04, Vol.94 (8), p.1130-1135

2006

Volltextzugriff (PDF)

2010 A genetic variant in RASSF1A, a key regulator of HIPPO pathway, predicts survival in two independent cohorts of mCRC patients treated with cetuximab-based chemotherapy

European journal of cancer (1990), 2015-09, Vol.51, p.S331-S331

2015

Volltextzugriff (PDF)

Phase II trial of combination therapy of gemcitabine plus anti-angiogenic vaccination of elpamotide in patients with advanced or recurrent biliary tract cancer

Investigational new drugs, 2015-04, Vol.33 (2), p.490-495

2015

Volltextzugriff (PDF)

Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer

British journal of cancer, 2004-10, Vol.91 (7), p.1245-1250

2004

Volltextzugriff (PDF)

2100 Impact of UGT1A1 genotype and irinotecan exposure on outcomes in Japanese patients with advanced colorectal cancer treated by irinotecan-based regimens

European journal of cancer (1990), 2015-09, Vol.51, p.S362-S362

2015

Volltextzugriff (PDF)

Depth of invasion parallels increased cyclooxygenase‐2 levels in patients with gastric carcinoma

Cancer, 2001-05, Vol.91 (10), p.1876-1881

2001

Volltextzugriff (PDF)

The Unanswered Question: What Is the Determinant of S-1 Pharmacokinetics?

Clinical pharmacology and therapeutics, 2008-08, Vol.84 (2), p.203-203

2008

Volltextzugriff (PDF)

Pharmacokinetics of 5-fluorouracil in elderly Japanese patients with cancer treated with S-1 (a combination of tegafur and dihydropyrimidine dehydrogenase inhibitor 5-chloro-2,4-dihydroxypyridine)

Drug metabolism and disposition, 2009-07, Vol.37 (7), p.1375-1377

2009

Volltextzugriff (PDF)

38P Modified (m)-FOLFOXIRI plus cetuximab versus bevacizumab for right-sided or BRAF mutant metastatic colorectal cancer (mCRC): Subgroup analysis of the DEEPER trial (JACCRO CC-13)

Annals of oncology, 2024-06, Vol.35, p.S20-S20

2024

Volltextzugriff (PDF)

P-57 An observational/translational study of BRAF inhibitor combination therapy for BRAF-mutant metastatic colorectal cancer including biomarker research: BEETS trial (JACCRO CC-18)

Annals of oncology, 2022-06, Vol.33, p.S267

2022

Volltextzugriff (PDF)

1 – 25 von 816

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(710)
Mit Volltextzugriff
(688)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(796)
Japanisch
(23)
Deutsch
(1)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

No benefit from the addition of anti-EGFR antibody in all right-sided metastatic colorectal cancer?

An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients

Relation of overall survival, progression free survival, post progression survival and response rate in four randomized Japanese phase III trials comparing various combinations of S-1 therapy for first-line treatment of advanced gastric cancer

Phase II study of third-line panitumumab rechallenge in patients with metastatic wild-type KRAS colorectal cancer who achieved a clinical benefit in response to first-line panitumumab plus chemotherapy

Correlation between tumor response to first-line chemotherapy and prognosis in advanced gastric cancer patients

Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05)

RAS mutations in circulating tumor DNA (ctDNA) and clinical outcomes of rechallenge treatments with anti-EGFR antibodies in patients with metastatic colorectal cancer (mCRC)

Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer

A biomarker study to validate predictors for clinical outcome of cetuximab based chemotherapy in first-line metastatic colorectal cancer (mCRC) patients: JACCRO CC-05/06AR and FIRE-3

Gene mutation status in circulating tumor DNA (ctDNA) and first-line FOLFOXIRI plus bevacizumab (bev) in metastatic colorectal cancer (mCRC) harboring RAS mutation

CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy

Dynamic changes in RAS gene status in circulating tumour DNA: a phase II trial of first-line FOLFOXIRI plus bevacizumab for RAS-mutant metastatic colorectal cancer (JACCRO CC-11)

Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16

Genetic testing for UGT1A128 and 6 in Japanese patients who receive irinotecan chemotherapy

A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials

Phase I II study of S-1 combined with irinotecan for metastatic advanced gastric cancer

2010 A genetic variant in RASSF1A, a key regulator of HIPPO pathway, predicts survival in two independent cohorts of mCRC patients treated with cetuximab-based chemotherapy

Phase II trial of combination therapy of gemcitabine plus anti-angiogenic vaccination of elpamotide in patients with advanced or recurrent biliary tract cancer

Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer

2100 Impact of UGT1A1 genotype and irinotecan exposure on outcomes in Japanese patients with advanced colorectal cancer treated by irinotecan-based regimens

Depth of invasion parallels increased cyclooxygenase‐2 levels in patients with gastric carcinoma

The Unanswered Question: What Is the Determinant of S-1 Pharmacokinetics?

Pharmacokinetics of 5-fluorouracil in elderly Japanese patients with cancer treated with S-1 (a combination of tegafur and dihydropyrimidine dehydrogenase inhibitor 5-chloro-2,4-dihydroxypyridine)

38P Modified (m)-FOLFOXIRI plus cetuximab versus bevacizumab for right-sided or BRAF mutant metastatic colorectal cancer (mCRC): Subgroup analysis of the DEEPER trial (JACCRO CC-13)

P-57 An observational/translational study of BRAF inhibitor combination therapy for BRAF-mutant metastatic colorectal cancer including biomarker research: BEETS trial (JACCRO CC-18)

Suchergebnisse filtern